Critical Outcome Tec (COTQF) 0.5180 $COTQF
Critical Outcome Technologies Announces Additional Funding Through Warrant Exercises
Marketwired - Mon May 02, 7:01AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
announced today that all the common share purchase warrants and compensation warrants issued in a private placement financing that closed on April 30, 2014, as previously announced, were exercised prior to their expiry on April 29, 2016. The Company realized gross proceeds of $992,990 and issued 3,598,250 common shares upon exercise of the warrants.
COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Augments Advisory Board Drug Development Experience
Marketwired - Wed Apr 27, 7:01AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company" announced today the addition of Dr. Nancy Chang to its Scientific Advisory Board to support the Company in the clinical development of its lead cancer drug candidate, COTI-2, and its other pipeline compounds.
COT.VN: 0.660 (-0.010)
Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
Marketwired - Tue Apr 19, 7:31AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT) (OTCQB: COTQF), announced today that the Company commenced treating patients in the second cohort of its ongoing Phase 1 clinical trial of COTI-2 for the treatment of gynecological cancers. Treatment of the second cohort will continue to evaluate COTI-2's safety profile at a dosage level twice that of the first cohort. Prior to initiating cohort two, the independent Dose Escalation Committee reviewed the safety data from all patients in the first cohort and unanimously approved moving to dosing the next cohort.
COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Completes Private Placement With a Successful U.S. Life Science Investor
Marketwired - Wed Mar 30, 7:15AM CDT
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Provides Market Update
Marketwired - Tue Mar 22, 1:42PM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company" announced at the request of IIROC that its continuous disclosure responsibilities are up to date and all material transactions and news in this regard have been disclosed to the market.
COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Announces Funding Received Through Warrant Exercises
Marketwired - Thu Mar 17, 7:31AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company" announced today that it realized gross proceeds of $1,447,125 upon the exercise of 4,823,750 common share purchase warrants that would otherwise have expired on March 15, 2016. The warrants exercised were part of a private placement financing previously announced in March and April 2011 that resulted in the issuance of common share purchase warrants exercisable at $0.30 per common share.
COT.VN: 0.660 (-0.010)
Critical Outcome Launches Rosalind -- A Precision Medicine Platform Designed to Provide Cancer Treatment Options
Marketwired - Mon Mar 14, 8:13AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT) (OTCQB: COTQF), announced today the launch of ROSALIND(TM), a smart data platform designed to provide personalized drug treatment options for cancer patients based on the genetic mutation and expression profile of an individual's tumor. Using advanced algorithms for dealing with big data problems, ROSALIND makes it possible to evaluate what available drug treatments may be effective for an individual's specific cancer while minimizing potential side effects using advanced algorithms.
COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Reports Fiscal 2016 Third Quarter Financial and Operating Results
Marketwired - Fri Mar 11, 3:05PM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company" reported its financial and operating results today for the three and nine month periods ended January 31, 2016.
COT.VN: 0.660 (-0.010)
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 5.26 (-0.11), CLDX: 4.62 (-0.10), BMY: 74.81 (+0.15)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.45 (-0.02), AMBX: (), CLDX: 4.62 (-0.10), ARQL: 1.66 (+0.03), CTIC: 0.34 (+0.01), CTMX: 10.06 (+0.04), ABBV: 66.23 (+1.51), XLRN: 33.92 (-0.01), ADXS: 8.34 (+0.16), AMGN: 172.03 (+0.75), BIND: 0.78 (-0.09), BMY: 74.81 (+0.15), BPTH: 1.70 (-0.04), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), CELGZ: 1.16 (-0.01)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.65 (+0.04), CVM: 0.45 (-0.02), CLDX: 4.62 (-0.10), IMGN: 2.78 (-0.01), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), BIND: 0.78 (-0.09), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), ABBV: 66.23 (+1.51), XLRN: 33.92 (-0.01)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 14.68 (-0.24), AMBX: (), CLBS: 5.54 (+0.08), CANF: 2.10 (+0.03), APTO: 2.52 (+0.02), AVXL: 3.84 (+0.33), BPTH: 1.70 (-0.04), AZN: 34.14 (-0.15), CYAD: 24.98 (-0.02)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 90.21 (+2.09), IMGN: 2.78 (-0.01), ARQL: 1.66 (+0.03), LLY: 82.89 (-0.04), GSK: 45.07 (-0.11), ONTY: 1.21 (+0.02), MDVN: 63.99 (+1.50), MRK: 58.66 (+0.23), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), GALE: 0.44 (-0.03), PBYI: 49.89 (+1.37), NVS: 83.26 (+1.18), KPTI: 7.38 (+0.02), XLRN: 33.92 (-0.01), EXEL: 9.18 (+0.23)
HIV-1 Infection - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8h7d/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Beth Israel Deaconess Medical Center, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Chipscreen Biosciences Ltd - CompleGen, Inc. - Critical Outcome Technologies Inc. - Cytodyn Inc. - Dong-A ST Co., Ltd. - Enzo Biochem, Inc. - Evofem, Inc. - FIT Biotech Oy - Formune S.L. - Frontier Biotechnologies Co., Ltd - GeneCure LLC - Genetic Immunity, Inc - Gilead Sciences, Inc. - GlaxoSmithKline Plc - H-Phar S.A. - Heat Biologics, Inc. - (20 Others) For more information visit http://www.researchandmarkets.com/research/px..._infection
HTBX: 0.71 (-0.01), ARGS: 5.26 (-0.11), ENZ: 6.97 (+0.27), GILD: 79.47 (-1.77), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15)
Global Peritoneal Cancer Therapeutics Pipeline Review H2 2015
M2 - Thu Jan 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dwpnp/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peritoneal Cancer Overview - Therapeutics Development - Pipeline Products for Peritoneal Cancer - Overview - Pipeline Products for Peritoneal Cancer - Comparative Analysis - Peritoneal Cancer - Therapeutics under Development by Companies - Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes - Peritoneal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peritoneal Cancer - Products under Development by Companies - Peritoneal Cancer - Products under Investigation by Universities/Institutes - Peritoneal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Advanced Accelerator Applications SA - Amgen Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Atara Biotherapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Beth Israel Deaconess Medical Center, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Celldex Therapeutics, Inc. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Corcept Therapeutics Incorporated - Critical Outcome Technologies Inc. - CritiTech, Inc. - CTI BioPharma Corp. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Galena Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/9d...eal_cancer
CERU: 2.89 (+0.14), CLDX: 4.62 (-0.10), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), ATRA: 24.00 (-0.05), CTIC: 0.34 (+0.01), CLBS: 5.54 (+0.08), AAAP: 31.29 (+0.29), CLSN: 1.23 (unch), CLVS: 14.28 (+0.25), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), GALE: 0.44 (-0.03), ABBV: 66.23 (+1.51), CORT: 5.80 (-0.06), EXEL: 9.18 (+0.23), XLRN: 33.92 (-0.01), ARRY: 3.74 (-0.03)
Critical Outcome Technologies Announces Additional Funding Through Warrant Exercises
Marketwired - Mon May 02, 7:01AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
announced today that all the common share purchase warrants and compensation warrants issued in a private placement financing that closed on April 30, 2014, as previously announced, were exercised prior to their expiry on April 29, 2016. The Company realized gross proceeds of $992,990 and issued 3,598,250 common shares upon exercise of the warrants. COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Augments Advisory Board Drug Development Experience
Marketwired - Wed Apr 27, 7:01AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
announced today the addition of Dr. Nancy Chang to its Scientific Advisory Board to support the Company in the clinical development of its lead cancer drug candidate, COTI-2, and its other pipeline compounds. COT.VN: 0.660 (-0.010)
Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
Marketwired - Tue Apr 19, 7:31AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT) (OTCQB: COTQF), announced today that the Company commenced treating patients in the second cohort of its ongoing Phase 1 clinical trial of COTI-2 for the treatment of gynecological cancers. Treatment of the second cohort will continue to evaluate COTI-2's safety profile at a dosage level twice that of the first cohort. Prior to initiating cohort two, the independent Dose Escalation Committee reviewed the safety data from all patients in the first cohort and unanimously approved moving to dosing the next cohort. COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Completes Private Placement With a Successful U.S. Life Science Investor
Marketwired - Wed Mar 30, 7:15AM CDT
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Provides Market Update
Marketwired - Tue Mar 22, 1:42PM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
announced at the request of IIROC that its continuous disclosure responsibilities are up to date and all material transactions and news in this regard have been disclosed to the market. COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Announces Funding Received Through Warrant Exercises
Marketwired - Thu Mar 17, 7:31AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
announced today that it realized gross proceeds of $1,447,125 upon the exercise of 4,823,750 common share purchase warrants that would otherwise have expired on March 15, 2016. The warrants exercised were part of a private placement financing previously announced in March and April 2011 that resulted in the issuance of common share purchase warrants exercisable at $0.30 per common share. COT.VN: 0.660 (-0.010)
Critical Outcome Launches Rosalind -- A Precision Medicine Platform Designed to Provide Cancer Treatment Options
Marketwired - Mon Mar 14, 8:13AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT) (OTCQB: COTQF), announced today the launch of ROSALIND(TM), a smart data platform designed to provide personalized drug treatment options for cancer patients based on the genetic mutation and expression profile of an individual's tumor. Using advanced algorithms for dealing with big data problems, ROSALIND makes it possible to evaluate what available drug treatments may be effective for an individual's specific cancer while minimizing potential side effects using advanced algorithms. COT.VN: 0.660 (-0.010)
Critical Outcome Technologies Reports Fiscal 2016 Third Quarter Financial and Operating Results
Marketwired - Fri Mar 11, 3:05PM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
reported its financial and operating results today for the three and nine month periods ended January 31, 2016. COT.VN: 0.660 (-0.010)
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 5.26 (-0.11), CLDX: 4.62 (-0.10), BMY: 74.81 (+0.15)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.45 (-0.02), AMBX: (), CLDX: 4.62 (-0.10), ARQL: 1.66 (+0.03), CTIC: 0.34 (+0.01), CTMX: 10.06 (+0.04), ABBV: 66.23 (+1.51), XLRN: 33.92 (-0.01), ADXS: 8.34 (+0.16), AMGN: 172.03 (+0.75), BIND: 0.78 (-0.09), BMY: 74.81 (+0.15), BPTH: 1.70 (-0.04), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), CELGZ: 1.16 (-0.01)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.65 (+0.04), CVM: 0.45 (-0.02), CLDX: 4.62 (-0.10), IMGN: 2.78 (-0.01), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), BIND: 0.78 (-0.09), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), ABBV: 66.23 (+1.51), XLRN: 33.92 (-0.01)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 14.68 (-0.24), AMBX: (), CLBS: 5.54 (+0.08), CANF: 2.10 (+0.03), APTO: 2.52 (+0.02), AVXL: 3.84 (+0.33), BPTH: 1.70 (-0.04), AZN: 34.14 (-0.15), CYAD: 24.98 (-0.02)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 90.21 (+2.09), IMGN: 2.78 (-0.01), ARQL: 1.66 (+0.03), LLY: 82.89 (-0.04), GSK: 45.07 (-0.11), ONTY: 1.21 (+0.02), MDVN: 63.99 (+1.50), MRK: 58.66 (+0.23), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), GALE: 0.44 (-0.03), PBYI: 49.89 (+1.37), NVS: 83.26 (+1.18), KPTI: 7.38 (+0.02), XLRN: 33.92 (-0.01), EXEL: 9.18 (+0.23)
HIV-1 Infection - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8h7d/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Beth Israel Deaconess Medical Center, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Chipscreen Biosciences Ltd - CompleGen, Inc. - Critical Outcome Technologies Inc. - Cytodyn Inc. - Dong-A ST Co., Ltd. - Enzo Biochem, Inc. - Evofem, Inc. - FIT Biotech Oy - Formune S.L. - Frontier Biotechnologies Co., Ltd - GeneCure LLC - Genetic Immunity, Inc - Gilead Sciences, Inc. - GlaxoSmithKline Plc - H-Phar S.A. - Heat Biologics, Inc. - (20 Others) For more information visit http://www.researchandmarkets.com/research/px..._infection
HTBX: 0.71 (-0.01), ARGS: 5.26 (-0.11), ENZ: 6.97 (+0.27), GILD: 79.47 (-1.77), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15)
Global Peritoneal Cancer Therapeutics Pipeline Review H2 2015
M2 - Thu Jan 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dwpnp/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peritoneal Cancer Overview - Therapeutics Development - Pipeline Products for Peritoneal Cancer - Overview - Pipeline Products for Peritoneal Cancer - Comparative Analysis - Peritoneal Cancer - Therapeutics under Development by Companies - Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes - Peritoneal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peritoneal Cancer - Products under Development by Companies - Peritoneal Cancer - Products under Investigation by Universities/Institutes - Peritoneal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Advanced Accelerator Applications SA - Amgen Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Atara Biotherapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Beth Israel Deaconess Medical Center, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Celldex Therapeutics, Inc. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Corcept Therapeutics Incorporated - Critical Outcome Technologies Inc. - CritiTech, Inc. - CTI BioPharma Corp. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Galena Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/9d...eal_cancer
CERU: 2.89 (+0.14), CLDX: 4.62 (-0.10), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), ATRA: 24.00 (-0.05), CTIC: 0.34 (+0.01), CLBS: 5.54 (+0.08), AAAP: 31.29 (+0.29), CLSN: 1.23 (unch), CLVS: 14.28 (+0.25), AZN: 34.14 (-0.15), AVEO: 1.00 (-0.01), GALE: 0.44 (-0.03), ABBV: 66.23 (+1.51), CORT: 5.80 (-0.06), EXEL: 9.18 (+0.23), XLRN: 33.92 (-0.01), ARRY: 3.74 (-0.03)
